Fig. 7

Resveratrol + ursolic acid protect against cytokine-induced inflammation in human ARPE-19 and RPE cells. A and B Different concentrations of resveratrol and ursolic acid (0, 100, 500, 1000, 2000, and 4000 ng) were applied for 72 h. Cell viability was determined using MTS assay. C Different concentrations of resveratrol + ursolic acid (0, 100, 500, 1000, 2000, and 4000 ng/ml) were administered for 72 h. Cell viability was determined using the MTS assay. D, E, and F ARPE-19 cells were pretreated with 5 ng/ml of IL-6 + TNF-α for 2 h and then treated with resveratrol, ursolic acid, and resveratrol + ursolic acid (1000 ng/ml) and incubated for 6 h. Expressions of IL-6, IL-8, and, TNF-α in ARPE-19 cells were measured using the ELISA Ready-Set-Go kit. G, H, and I H-RPE cells were pretreated with 5 ng/ml of IL-6 + TNF-α for 2 h and then administered resveratrol, ursolic acid, and resveratrol + ursolic acid (1000 ng/ml) and incubated for 6 h. Expressions of IL-6, IL-8, and TNF-α in H-RPE cells were measured using the ELISA Ready-Set-Go kit. The data are expressed as the mean  ±  SD of three independent experiments. * p < 0.05 compared with the control